[HONG KONG,December 31, 2021] Great Bay Bio (GBB), an AI-enabled biotechnology company,announces the participation of FutureX Capital in its Series A roundfundraising.

Taili Biotech, a wholly-owned domestic subsidiary of Great Bay Bio (GBB), won the Special Prize of NVIDIA Start-up Final Showcase. Dr. Deng Xinyu, CTO of GBB, was invited to participate in the NVIDIA 2021 Data Lake Conference and presented a live broadcas

[HONG KONG, December 1, 2021] Great Bay Bio (hereinafter referred to as “GBB”) is pleased to announce today the completion of its near USD 10M series A fundraising led by Proxima Ventures.

[HONG KONG, November 4, 2021] Recently, Great Bay Bio (GBB) has been invited to participate in the NVIDIA Inception Program initiated by NVIDIA, a global GPU giant and AI computing industry leader.

[Hong Kong, September 18, 2021] Recently, Mr. Kingsley Leung, Chairman of Great Bay Bio Holdings Limited (hereinafter referred to as “GBB”)

[HONG KONG, August 20, 2021] Recently, the 2021 Merck Greater Bay Area Innovation Bootcamp was held in Guangzhou. After comprehensive consideration and careful evaluation by Merck China and global experts from multiple dimensions such as technical foresig

[HONG KONG, August 16,2021] Recently, Great Bay Bio Holdings Limited (hereinafter referred to as“GBB”) was listed in SCMP’s AsiaSustainability Conference, expecting to rank as one of the TOP 10 mostpotential start-ups by the South China Morning Post (SCMP

[July 5, 2021 - Hong Kong] Great Bay Bio Holdings Limited (hereinafter referred to as “GBB”) announces that the company’s self-developed intelligent cell line stability prediction platform AlfaStaX, is officially launched. Given the easy accessibility an